Click here to join

At the cutting edge

At the
cutting edge.

Research for life

for life.

Innovation and performance

Innovation and


What's new.

December 16th 2021
press releases

For a copy of this Analyst report please contact your Jefferies advisor.

December 1st 2021
analyst reports
November 26th 2021
press releases
November 26th 2021
press releases
November 26th 2021
press releases

Upcoming Events

What's next.

February 14th 2022 - February 17th 2022

read more
April 4th 2022 - April 6th 2022

read more

Who we are

About us.


It takes a great deal of passion to pursue the fight against cancer and autoimmune diseases. We put our heart and soul into winning it.


Our goal is to gather the strongest forces, the brightest minds and the most dedicated employees.


Accurate research and development is the strongest foundation for developing effective treatments.

What is LAG-3?
Lymphocyte-activation gene 3, or LAG-3 (LAG-3), is a gene that provides the genetic information to make a cell surface molecule with biologic effects on T cell function.
LAG-3 is being used for many immunotherapy treatments including Eftilagimod Alpha from Immutep.